Table 3

*Groups*					*Markers*
Zileuton treated	Montelukast treated	Pc	AC	NC	*Markers*
Moderate**	Moderate**	Very strong *	Very strong *	Negative	VCAM-1
Moderate **	Moderate **	Very strong*	Very strong*	Negative	MCP-1
Moderate **	Moderate **	Very strong*	Very strong*	Negative	TNF-α
Moderate **	Moderate **	Very strong*	Very strong*	Negative	IL-17

*p < 0.05, as compare to NC group. **p < 0.05, as compare to PC group

Table 3: The difference in median tissue (VCAM-1, MCP-1,IL17 and TNF alfa )immunostain intensity among the five study groups.